江苏东星智慧医疗科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况汇总表 汇总表 第 1 页 本表已于 2025 年 4 月 14 日获董事会批准。 公司负责人（法定代表人）：_________ 主管会计工作负责人：________ 会计机构负责人：________ 单位：万元 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算 的会计科目 2024 年期初 占用资金余 额 2024 年度占用 累计发生金额 （不含利息） 2024 年度占 用资金的利息 (如有) 2024 年度偿 还累计发生 金额 2024 年期 末占用资 金余额 占用形成 原因 占用性质 控股股东、实际控制 人及其附属企业 小计 - - - - - 前控股股东、实际控 制人及其附属企业 小计 - - - - - 其他关联方及附属 企业 小计 总计 - - - - - 其它关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算 的会计科目 2024 年期初 往来资金余 额 2024 年度往来 累计发生金额 （不含利息） 2024 年度往 来资金的利息 (如有) 2024 年度偿 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-010 江苏东星智慧医疗科技股份有限公司 关于召开公司2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于2025年4月14日召 开了第四届董事会第八次会议，审议通过了《关于提请召开2024年年度股东大 会的议案》，董事会决定于2025年5月6日（星期二）下午2:30在公司会议室召 开2024年年度股东大会。为了进一步保护投资者的合法权益，方便公司股东行 使表决权，本次股东大会将采用现场投票与网络投票相结合的方式，根据有关 规定，现将股东大会的相关事项通知如下： 1、股东大会届次：2024年年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第八次会议审议通过了《 关于提请召开2024年年度股东大会的议案》，本次股东大会的召开符合有关法 律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章 程》的规定。 4、会议召开时间： 现场会议召开时间：2025年5月6日（星期 ...

一、监事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届监事会第 七次会议于 2025 年 4 月 14 日 12:30 在公司会议室以现场方式召开。本次会议通 知已于 2025 年 4 月 3 日通过邮件的方式送达全体监事。本次会议由监事会主席 朱慧玲主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席会 议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定。 二、监事会会议审议情况 与会监事经过审议，表决通过了以下议案： 证券代码：301290 证券简称：东星医疗 公告编号：2025-005 江苏东星智慧医疗科技股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （一）审议通过《关于公司<2024 年度监事会工作报告>的议案》 经审议，监事会认为：2024 年公司监事会全体成员根据《公司法》、《证 券法》及其他相关法律、法规、规章以及《公司章程》等有关规定，本着对全体 股东负责的态度，从切实维护公司利益和股东权益出发，认真地履行了监事会职 ...

（一）审议通过《关于公司<2024 年度总经理工作报告>的议案》 经审议，董事会认真听取了总经理魏建刚先生所作的《2024 年度总经理工 作报告》，认为 2024 年度公司经营管理层有效执行了董事会、股东大会的各项 决议，使公司保持了持续稳定的发展，该报告客观、真实地反映了经营管理层 2024 年度主要工作及取得的成果。 证券代码：301290 证券简称：东星医疗 公告编号：2025-004 江苏东星智慧医疗科技股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届董事会第八 次会议于 2025 年 4 月 14 日 8:30 在公司会议室以现场方式召开。本次会议通知 已于 2025 年 4 月 3 日通过邮件的方式送达全体董事。本次会议应出席董事 7 人， 实际出席董事 7 人。会议由董事长万世平先生召集并主持，公司监事、高级管理 人员列席了本次董事会。本次会议的召集、召开和表决程序符合《公司法》等有 关法律法规及《公司章程》的相关规定。 ...

二、利润分配预案的基本情况 证券代码：301290 证券简称：东星医疗 公告编号：2025-009 江苏东星智慧医疗科技股份有限公司 关于公司2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、审议程序 江苏东星智慧医疗科技股份有限公司(以下简称"公司")于2025年4月14日 召开第四届董事会第八次会议和第四届监事会第七次会议，审议通过了《关 于公司2024年度利润分配预案的议案》，本议案尚需公司2024年年度股东大 会审议。 经立信会计师事务所(特殊普通合伙)审计，公司2024年度母公司实现净 利润59,685,352.88元，提取法定盈余公积金4,381,177.03元，加上年初未分 配利润317,226,851.67元，扣除已支付2023年度现金分红59,362,969.80元， 实际可供分配利润为313,168,057.72元。公司2024年度合并报表可供分配利 润为430,620,595.25元。根据《深圳证券交易所上市公司自律监管指引第2号 —创业板上市公司规范运作》规定，按照合并报表、母公司报表中可供分配 利润孰 ...

Financial Performance - In 2024, the company achieved operating revenue of CNY 435.46 million and a net profit attributable to shareholders of CNY 97.42 million[3]. - The company's operating revenue for 2024 was ¥435,463,080.43, representing a 0.40% increase compared to ¥433,734,971.84 in 2023[5]. - The net profit attributable to shareholders for 2024 was ¥97,424,753.19, a slight increase of 0.21% from ¥97,222,808.88 in 2023[5]. - The net profit after deducting non-recurring gains and losses decreased by 2.49% to ¥66,459,147.18 in 2024 from ¥68,155,250.11 in 2023[5]. - The net cash flow from operating activities dropped by 22.46% to ¥126,492,238.66 in 2024, down from ¥163,133,094.63 in 2023[5]. - Total assets increased by 3.71% to ¥2,482,438,025.25 at the end of 2024, compared to ¥2,393,581,909.51 at the end of 2023[5]. - The company's basic earnings per share for 2024 was ¥0.98, a 1.03% increase from ¥0.97 in 2023[5]. - The gross margin for the fiscal year 2024 is projected to be 45%, up from 40% in 2023, due to improved operational efficiencies[21]. - The company reported a total revenue of 27,454,234 in the latest financial period[138]. Research and Development - The company invested CNY 22.43 million in R&D, resulting in the addition of 30 new patents, including 10 invention patents[4]. - The company plans to invest RMB 50 million in R&D for innovative medical technologies over the next two years[20]. - The company is developing a new type of disposable anastomosis device aimed at reducing processing costs and improving production efficiency[72]. - The company is focusing on technical innovation and product differentiation to expand its product range and attract more customers[74]. - The R&D team has seen a 57.89% increase in personnel with a bachelor's degree or higher, indicating a strategic shift towards high-tech fields[78]. - The company aims to optimize its R&D structure by implementing a "dual-talent" training mechanism to improve R&D efficiency[78]. - The company has developed high-tech laparoscopic staplers and is a pioneer in applying "non-equal height nails" technology, participating in drafting national industry standards[43]. Market Expansion and Strategy - In 2024, the company actively promoted its overseas market strategy, participating in multiple international medical exhibitions and forums[8]. - The company aims to expand its market presence in the Chongqing and Yunnan regions, targeting a 15% market share by the end of 2025[20]. - Future guidance estimates a revenue growth of 18% for 2025, driven by new product launches and market expansion strategies[21]. - The company has secured partnerships with three major hospitals in the Beijing area, enhancing its distribution network and expected to boost sales by 30% in 2024[20]. - The company aims to leverage the RCEP export tax policies to enhance its brand recognition and sales in overseas markets while exploring new emerging markets[119]. Product Development and Innovation - New product development includes a next-generation laparoscopic device expected to launch in Q3 2024, projected to increase sales by 10% in the first year[20]. - The company is developing a fully electric endoscopic stapler with intelligent feedback to enhance surgical precision and safety[77]. - The company has developed a new disposable circular cutting stapler and components, which reduces trauma and postoperative complications by replacing traditional circular cutting methods[75]. - The company is focusing on improving product performance and safety features in its new medical devices[75]. - The company is developing a new loading device for absorbable sutures, which aims to reduce the rate of defective sutures and enhance hemostatic performance[74]. Financial Management and Investments - The company plans to distribute a cash dividend of CNY 6 per 10 shares to shareholders, with no bonus shares issued[11]. - The company received government subsidies amounting to ¥8,577,280.45 in 2024, down from ¥15,701,171.44 in 2023[32]. - The company raised a total of RMB 1,104,160,596.06 through the issuance of 25,043,334 shares at a price of RMB 44.09 per share[101]. - After deducting issuance costs of RMB 101,587,913.35, the net proceeds amounted to RMB 1,002,572,682.71[101]. - The company has a stable cash dividend policy to ensure reasonable returns for investors, particularly focusing on the protection of minority shareholders' rights[185]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring a diverse and professional decision-making body[131]. - The company has a clear governance structure with separate decision-making mechanisms for the shareholders' meeting, board of directors, supervisory board, and management[134]. - The company has established a matrix management structure to ensure efficient implementation of strategic goals and effective execution of board decisions[132]. - The company has a dedicated human resources department that manages labor, compensation, and performance independently from controlling shareholders[134]. - The company is committed to maintaining high standards of corporate governance and transparency[140]. Social Responsibility and Compliance - The company donated a total of 600,000 RMB to charity during the reporting period, demonstrating its commitment to social responsibility[187]. - The company was recognized as a "Green Factory" by its subsidiary, indicating its commitment to environmental protection and sustainable development[187]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[184]. - The company has established measures to prevent the occupation of funds and assets, ensuring compliance with legal requirements[194]. Risks and Challenges - The company faces risks from volume-based procurement policies that may lead to price reductions for its products, potentially impacting revenue and profit margins[120]. - The company recognizes the risk of technological iteration in the medical device industry and aims to keep pace with market demands to maintain its competitive edge[122]. - The company is subject to regulatory requirements regarding the lock-up of shares held by major shareholders[191].

东星医疗（301290）公告，2024年营业收入4.35亿元，同比增长0.40%。归属于上市公司股东的净利润 9742.48万元，同比增长0.21%。基本每股收益0.98元/股，同比增长1.03%。公司拟向全体股东每10股派 发现金红利6元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Dongxing Medical, which closed at 23.56 yuan, up 1.46%, with a rolling PE ratio of 25.82 times and a total market value of 2.36 billion yuan [1][2] - The average PE ratio for the medical device industry is 45.14 times, with a median of 31.99 times, positioning Dongxing Medical at the 58th rank within the industry [1][2] - As of March 20, 2025, Dongxing Medical has 10,846 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - For the third quarter of 2024, the company reported revenue of 316 million yuan, a year-on-year increase of 1.57%, and a net profit of 65.58 million yuan, reflecting a year-on-year decrease of 8.17%, with a gross profit margin of 48.77% [2] - The company specializes in the research, production, and sales of surgical medical devices, particularly focusing on high-tech areas such as laparoscopic anastomosis devices [1][2] - Dongxing Medical is recognized as one of the early adopters of the "non-equal height nail" technology in the anastomosis device sector and has participated in drafting national industry standards [1]

2、 本所律师已按照依法制定的业务规则，采用了书面审查、查询、计算、 复核等方法，勤勉尽责、审慎履行了核查和验证义务。 北京市天元律师事务所 北京市天元律师事务所 关于江苏东星智慧医疗科技股份有限公司 控股股东、实际控制人增持公司股份的 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号国际企业大厦 A 座 509 单元 邮编：100033 关于江苏东星智慧医疗科技股份有限公司 控股股东、实际控制人增持公司股份的法律意见 京天股字（2025）第 025 号 致：江苏东星智慧医疗科技股份有限公司 北京市天元律师事务所（以下简称本所）接受江苏东星智慧医疗科技股份有 限公司（以下简称公司或东星医疗）委托，根据《中华人民共和国公司法》（以 下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公 司收购管理办法》（以下简称《收购管理办法》）、《深圳证券交易所上市公司自律 监管指引第 10 号-股份变动管理》（以下简称《股份变动管理指引》）等有关法律、 法规和规范性文件的规定及本法律意见出具日以前已经发生或者存在的事实，就 公司控股股东、实际控制人万世平先生及公司实际控制人万正元先生增持 ...

根据中国证监会《证券发行上市保荐业务管理办法》和《深圳证券交易所上 市公司自律监管指引第 13 号——保荐业务》等有关法律法规的要求，华泰联合 证券有限责任公司作为江苏东星智慧医疗科技股份有限公司（以下简称"东星医 疗"或"公司"）首次公开发行股票并在创业板上市的保荐人，于 2024 年 12 月 31 日对东星医疗 2024 年有关情况进行了现场检查，报告如下： | 保荐人名称：华泰联合证券有限责任公司 被保荐公司简称：东星医疗 | | | | | --- | --- | --- | --- | | 保荐代表人姓名：庄晨 联系电话：025-83388070 | | | | | 保荐代表人姓名：黄飞 联系电话：025-83387682 | | | | | 现场检查人员姓名：庄晨、黄飞 | | | | | 现场检查对应期间：2024 年度 | | | | | 现场检查时间：2024 年 12 月 31 日 | | | | | 一、现场检查事项 | | 现场检查意见 | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段：（1）查看公司办公楼、厂房、仓库等主要生产经营场所及募投项目建设情 况 ...